Xinnate AB
- Address
- Scheelevagen 2
Sponsor Overview
Specializations
Epidermolysis Bullosa
Xinnate AB’s clinical research is centered on epidermolysis bullosa, with attention to the severe skin fragility, chronic blistering, and difficult-to-heal wounds associated with the disease. The funded trial focuses on dystrophic epidermolysis bullosa and junctional epidermolysis bullosa, reflecting interest in inherited blistering disorders that require sustained dermatologic care.
- Wound healing
- Skin barrier repair
- Blistering and erosion management
- Dystrophic epidermolysis bullosa
- Junctional epidermolysis bullosa
The sponsor’s activity in this area is directed toward improving local skin outcomes and addressing the persistent symptom burden of inherited epidermolysis bullosa.
Dermatologic wound care
Research activity includes topical treatment of fragile skin lesions and open wounds, with emphasis on supporting re-epithelialization and reducing ongoing tissue damage. The clinical focus is on conditions where repeated skin injury creates a need for targeted wound care and symptom relief.
- Topical therapy
- Re-epithelialization
- Local tolerability
- Cutaneous lesions
This area reflects interest in practical dermatologic interventions for chronic, recurrent skin breakdown in inherited blistering disease.
Safety and tolerability in rare skin disease
The funded clinical work also examines safety and tolerability in patients with fragile skin, including local reactions at the treatment site. This is especially relevant in rare dermatologic disorders where treatment acceptability is as important as symptom improvement.
- Local skin tolerability
- Adverse skin reactions
- Patient comfort
- Rare disease dermatology
The sponsor’s research interest extends to treatment suitability in a population with marked skin sensitivity and ongoing wound burden.
Multinational rare disease research
Xinnate AB is involved in a multicountry clinical effort spanning several research sites in Europe and beyond, with activity across multiple countries. The trial network supports evaluation of therapies for rare inherited skin disease in a geographically diverse patient population.
- Rare disease collaboration
- International dermatology sites
- Inherited skin disorders
- Clinical access in Europe
This footprint places the sponsor within the field of specialized rare disease research focused on dermatologic conditions requiring coordinated international participation.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Safety, and Tolerability of Topical TCP-25 Gel in Epidermolysis Bullosa: A Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study |  France Greece Italy Spain Sweden | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 10 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
10 centres- Address
- Dragoumi Ionos 5 I, 161 21 Athens
- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Roma, Via Dei Monti Di Creta 104, 00167 Rome
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Calle Villarroel 170, 08036 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Xinnate AB.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.